Perspective Therapeutics Inc

CATX remains in a high-confidence Stage 4 decline, trading below all major moving averages with no active patterns to support a rally. Medium-term bearish structure is intact under a sequence of lower highs and lower lows, and short-term conditions show a lack of upside follow-through into declining EMAs. Execution should focus on selling into any relief rallies around the 9/21 EMA zone. A decisive close and hold above those EMAs would invalidate the bearish bias.

• ↑Completed PSV359 Phase1/2a dosing, enabling next pivotal trials.
• ↑Analyst consensus Buy with $11.50 target implies 248.5% upside.
• ↓Q2 net loss $26.8M strains cash runway amid revenue shortfall.